VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    NEXT STORY
    Exagen Inc. Announces $26.2 Million Debt Refinancing
    PREV STORY
    Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted

    Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office ...

    author_avatar
    NASDAQ Market News

    Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results

    author_avatar
    NASDAQ Market News

    Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

    author_avatar
    NASDAQ Market News